Ads
related to: new procedure for stroke patients with dementia treatment protocol guidelines- Alzheimer's Disease Info
Learn About the Stages of AD &
Diagnostic Tests for Patients.
- Getting Started
Read Infusion FAQs & Tips For
Getting Started With Treatment.
- Support & Resources
Access Downloadable Patient
Resources Available On-Site.
- For Care Partners
Help Support Your Loved One. See
Helpful Tips & Resources.
- Alzheimer's Disease Info
Search results
Results From The WOW.Com Content Network
Latest stroke prevention guidelines highlight the importance of lifestyle interventions for cardiovascular health and managing conditions such as type 2 diabetes and high blood pressure.
Since stroke is an essential part of vascular dementia, [13] the goal is to prevent new strokes. This is attempted through reduction of stroke risk factors, such as high blood pressure, high blood lipid levels, atrial fibrillation, or diabetes mellitus. [2] [5] Medications for high blood pressure are used to prevent pre-stroke dementia. [19]
Hemorrhagic stroke is a rare but serious complication of thrombolytic therapy. If a patient has had thrombolysis before, an allergy against the thrombolytic drug may have developed (especially after streptokinase). If the symptoms are mild, the infusion is stopped and the patient is commenced on an antihistamine before infusion is recommenced.
Treatment INDs are filed to make a drug available for the treatment of serious or immediately life-threatening conditions prior to FDA approval. Serious diseases or conditions are stroke, schizophrenia, rheumatoid arthritis, osteoarthritis, chronic depression, seizures, Alzheimer's dementia, amyotrophic lateral sclerosis (ALS), and narcolepsy.
If MSC treatment becomes available for stroke patients, it is possible that current mortality and morbidity rates could substantially improve due to the direct enhancement of neuroprotection and neurorestoration mechanisms rather than only indirect facilitation or prevention of further damage, e.g. decompressive surgery.
The 2015 DLBC in the United States is a project of the Parkinson's Disease BioMarker Program of the National Institute of Neurological Disorders and Stroke that "establishes a group of centers dedicated to the study of dementia with Lewy bodies (DLB) ... to allow for the discovery of a biomarker for DLB to improve the diagnosis, care, and treatment of patients with this disease".
Ads
related to: new procedure for stroke patients with dementia treatment protocol guidelines